{"id":"W2996164021","doi":"10.1016/j.clgc.2019.12.007","title":"Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Health Services; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Foundation Medicine; Genentech; Ipsen; Bayer; Calithera Biosciences; Bristol-Myers Squibb Canada; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; F. Hoffmann-La Roche; Pfizer Canada; Alexion Pharmaceuticals; Dana-Farber Cancer Institute; Roche; Novartis; Exelixis; Sanofi; Merck; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen; Pfizer; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Hazard ratio; Discontinuation; Renal cell carcinoma; Internal medicine; Odds ratio; Oncology; Confidence interval; Retrospective cohort study; Kidney cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004927132,0.0002113708,0.0008852088,0.0002929667,0.0003858079,0.0008264777,0.0002576694,0.0004249581,0.001318888],"category_scores_gemma":[0.002265777,0.0001078333,0.001662386,0.000455665,0.000210869,0.0006379465,0.0003297749,0.0008670258,0.0001751727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00114949,"about_ca_system_score_gemma":0.0008018712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002524852,"about_ca_topic_score_gemma":0.005596635,"domain_scores_codex":[0.9996562,0.00006082199,0.00004017731,0.00006552597,0.00006137084,0.0001159674],"domain_scores_gemma":[0.9989599,0.0002221518,0.0003535184,0.00003324048,0.0001175358,0.0003135876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02432836,0.000730398,0.9043726,0.000370606,0.001509379,0.0006774625,0.000134549,0.002445948,0.001323639,0.0001644062,0.002432888,0.06150983],"study_design_scores_gemma":[0.0007625347,0.006550737,0.9852428,0.0001103584,0.001419947,0.001063999,0.0002091804,0.001641195,0.0006157887,0.0003024412,0.002041396,0.00003960088],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901813,0.006662232,0.0001121117,0.0003284448,0.00008111195,0.00002341636,0.0006709936,0.00001057281,0.001929789],"genre_scores_gemma":[0.9980262,0.0006149463,0.000032076,0.0001256889,0.00006093763,0.000009353755,0.0008490311,0.000002591634,0.0002790602],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002524852,"threshold_uncertainty_score":0.00834018,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03917808895234826,"score_gpt":0.3492407280194261,"score_spread":0.3100626390670779,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}